Pharm-136

Pharm-136, also known as 7-methyl-10-hydroxynoribogaminalog, is a serotonin 5-HT 2 receptor agonist and psychedelic drug of the ibogalog family.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Pharm-136, also known as 7-methyl-10-hydroxynoribogaminalog, is a serotonin 5-HT 2 receptor agonist and psychedelic drug of the ibogalog family.

Pharmacodynamics

Pharm-136 acts as a potent serotonin 5-HT 2 receptor agonist, with ( ) values of 0.6 nM (102%) at the serotonin 5-HT 2A receptor, 3.5 nM (52%) at the serotonin 5-HT 2B receptor, and 0.5 nM (101%) at the serotonin 5-HT 2C receptor. The drug showed far lower agonistic potency or was inactive at all other serotonin receptors.

As an agonist of the serotonin 5-HT 2A receptor in vitro, Pharm-136 showed 29-fold greater potency as well as higher efficacy (101% vs. 80%) than psilocin. The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. Its median effective dose (ED 50 ) was 3.6 mg/kg, compared to 0.38 mg/kg (9.5-fold lower) in the case of psilocybin.

Pharmacokinetics

The preclinical pharmacokinetics of Pharm-136 have been studied.

Chemistry

Pharm-136 is an ibogalog (azepinoindole) derivative and a cyclized tryptamine analogue of the non-hallucinogenic psychoplastogen 7-methylpsilocin.

Synthesis

The chemical synthesis of Pharm-136 has been described.

History

Pharm-136 was patented by Bright Minds Biosciences in 2023. There is interest in Pharm-136 for potential therapeutic use.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370149759 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.